Original ResearchThe clinical outcomes of vaginoplasty using tissue-engineered biomaterial mesh in patients with Mayer-Rokitansky-Küster-Hauser syndrome

- Evaluate the clinical outcomes of vaginoplasty in patients with Mayer-Rokitansky-Küster-Hauser syndrome (MRKHS).
- All patients answered the FSFI questionnaire and the mean total FSFI score was 25.2.
- The vaginoplasty could act as a safe and effective surgical treatment for patients with MRKHS.

ObjectiveThe aim of the study is to evaluate the clinical outcomes of vaginoplasty using tissue-engineered biomaterial mesh in the patients with Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome.Patients and methodsPatients with MRKH syndrome underwent the vaginoplasty using tissue-engineered biomaterial mesh between January 2006 and August 2014 in PLA general hospital. We analyzed the anatomic results and collected the standardized FSFI (Female Sexual Function Index) questionnaire from each patient.ResultsTotally forty patients with MRKH syndrome were enrolled in the present study. The surgical procedures were performed without any major complication except that intraoperative bladder injury occurred in one case and was repaired successfully. The mean duration of surgery was 85.3 min (SD = 8.7), the mean blood loss was 58.7 ml (SD = 36.5). The mean hospital stay after surgery was 8.8 days (SD = 4.7). Three monthes after surgery, superduper mucosa was found in the neovagina of all enrolled patients. Twelve weeks after surgery, a satisfactory vaginal length of at least 9 cm was attained in all patients, and vaginal cross-sectional diameter more than 2 cm. The scar contracture, necrosis or rejection did not occurred in any patient. The anatomic success rate was 100%. All these sexually active patients answered the FSFI questionnaire and completed all the 19 items in the questionnaire. The mean total FSFI score of these patients was 25.2.ConclusionsThe vaginoplasty using tissue-engineered biomaterial mesh procedure can act as a safe and effective surgical strategy for patients with MRKH syndrome. However, larger scale studies with longer follow-up profiles are needed to justify its widespread utilization.